Molars and incisors were excised from the mandibles of 15-day-old mouse embryos and explanted to agar-solidified Eagle’s basal medium with 10% fetal calf serum and to medium containing 6-diazo-5-oxonorleucine (DON), a glutamine analog which inhibits glycoprotein and glycosaminoglycan synthesis. The concentration of DON ranged from 5-100 µg/ml; the lowest dose at which consistent results were obtained was 75 µg/ml. At the end of a 4-day culture period, controls displayed characteristic incisiform or molariform morphologies and possessed odontoblasts and preameloblasts. The growth and development of DON-treated germs, however, was arrested and such germs remained morphologically and histologically similar to the developmental state attained at the time of explantation. DON-treated germs also contained less abundant Alcian blue staining material than controls. Development arrest by DON was prevented by addition of glutamine but not by glucosamine or the purine analog amino imidazol carboximine. Suppressed germs resumed normal development when removed from medium containing 75 µg/ml of DON to control medium. These results suggest that glycoprotein or glycosaminoglycans play a role in epithelial-mesenchymal inductive interactions.

Keywords:
6-diazo-5-oxonorleucine (DON), Mouse tooth germs, Tooth development, Glycosaminoglycans, Suppression of tooth differentiation
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.